Xbrane Biopharma Swells In Oncology With Keytruda And Darzalex Projects
With Opdivo Biosimilar, Three Products ‘Could Be Launched In 2028-2029’
Xbrane Biopharma held a webcast with investors to mark the Swedish firm’s announcement to initiate development of two major new oncology biosimilar projects. CEO Martin Åmark delved into detail on how the programs fit into the company’s wider pipeline and Xbrane’s rigorous selection process.
